Neoadjuvant chemotherapy in urothelial bladder cancer: Impact of regimen and variant histology

Hristos Kaimakliotis, M. Francesca Monn, Jane S. Cho, Jose A. Pedrosa, Noah M. Hahn, Costantine Albany, Paul T. Gellhaus, K. Clinton Cary, Timothy Masterson, Richard Foster, Richard Bihrle, Liang Cheng, Michael Koch

Research output: Contribution to journalArticle

1 Scopus citations


Aim: We compared the efficacy of methotrexate/vinblastine/doxorubicin/cisplatin (MVAC) versus gemcitabine/cisplatin in urothelial cancer and neoadjuvant chemotherapy (NACT) efficacy in variant histology (VH). Materials & methods: Radical cystectomy patients were retrospectively compared with those who received NACT. Factors associated with survival, pathologic complete response (pCR) and downstaging (pDS) were evaluated in multivariable models. Results: 9% of radical cystectomy patients (84/919) received NACT, with improved survival, pCR and pDS on both regimens. MVAC lead to higher pDS without an increase in pCR. On multivariable analysis, there was a nonsignificant increase in pDS with MVAC. NACT conferred similar responses in squamous and glandular differentiation VH. Conclusion: NACT was associated with improved survival, pCR and pDS. Furthermore, responses to NACT were not dependent on presence of VH.

Original languageEnglish (US)
Pages (from-to)1795-1804
Number of pages10
JournalFuture Oncology
Issue number15
StatePublished - Aug 1 2016


  • bladder cancer
  • cystectomy
  • downstaging
  • neoadjuvant chemotherapy
  • pathologic response
  • variant histology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Neoadjuvant chemotherapy in urothelial bladder cancer: Impact of regimen and variant histology'. Together they form a unique fingerprint.

  • Cite this